m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00343)
Target Name Myeloid zinc finger 1 (MZF1)
Synonyms
MZF-1; Zinc finger and SCAN domain-containing protein 6; Zinc finger protein 42; MZF; ZNF42; ZSCAN6
    Click to Show/Hide
Gene Name MZF1
Chromosomal Location 19q13.43
Family krueppel C2H2-type zinc-finger protein family
Function
Binds to target promoter DNA and functions as transcription regulator. Regulates transcription from the PADI1 and CDH2 promoter. May be one regulator of transcriptional events during hemopoietic development.
    Click to Show/Hide
Gene ID 7593
Uniprot ID
MZF1_HUMAN
HGNC ID
HGNC:13108
Ensembl Gene ID
ENSG00000099326
KEGG ID
hsa:7593
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MZF1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line B16-OVA cell line Mus musculus
Treatment: shFTO B16-OVA cells
Control: shNC B16-OVA cells
 GSE154952
Regulation
logFC: -6.18E-01
p-value: 2.06E-02
More Results Click to View More RNA-seq Results
In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary GSK3beta inhibited Myeloid zinc finger 1 (MZF1) expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene c-Myc expression, thus hampering CRC cell proliferation.
Target Regulation Down regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Cell proliferation
In-vitro Model SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
HCT 8 Colon adenocarcinoma Homo sapiens CVCL_2478
In-vivo Model Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice.
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary FTO enhanced Myeloid zinc finger 1 (MZF1) expression by reducing m6A levels and mRNA stability in MZF1 mRNA transcript, leading to oncogenic functions. The functional importance of FTO in the tumor progression of LUSC and provides a potential therapeutic target for LUSC treatment.
Target Regulation Up regulation
Responsed Disease Lung squamous cell carcinoma ICD-11: 2C25.2
 Disease Info 
Cell Process mRNA stability
In-vitro Model 16HBE14o- Normal Homo sapiens CVCL_0112
BEAS-2B Normal Homo sapiens CVCL_0168
CHLH-1 (The human squamous lung cancer cell line)
NCI-H226 Pleural epithelioid mesothelioma Homo sapiens CVCL_1544
CHLH-1 (The human squamous lung cancer cell line)
NCI-H520 Lung squamous cell carcinoma Homo sapiens CVCL_1566
Colorectal cancer [ICD-11: 2B91]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary GSK3beta inhibited Myeloid zinc finger 1 (MZF1) expression by mediating FTO-regulated m6A modification of MZF1 and then decreased the proto-oncogene c-Myc expression, thus hampering CRC cell proliferation.
Responsed Disease Colorectal cancer [ICD-11: 2B91]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Ubiquitin mediated proteolysis hsa04120
Cell Process Cell proliferation
In-vitro Model SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
HCT 8 Colon adenocarcinoma Homo sapiens CVCL_2478
In-vivo Model Twenty-four specific pathogen free female BALB/c nude mice (age: 6 weeks, weight: 15 ~ 18 g) were purchased from Slac Laboratory Animal Co., Ltd., and subcutaneously injected with SW620 cells stably transfected with oe-NC, oe-GSK3-Beta + oe-NC, or oe-GSK3-Beta + oe-c-Myc to establish a subcutaneous xenograft tumour model in nude mice.
Lung cancer [ICD-11: 2C25]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary FTO enhanced Myeloid zinc finger 1 (MZF1) expression by reducing m6A levels and mRNA stability in MZF1 mRNA transcript, leading to oncogenic functions. The functional importance of FTO in the tumor progression of LUSC and provides a potential therapeutic target for LUSC treatment.
Responsed Disease Lung squamous cell carcinoma [ICD-11: 2C25.2]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Up regulation
Cell Process mRNA stability
In-vitro Model 16HBE14o- Normal Homo sapiens CVCL_0112
BEAS-2B Normal Homo sapiens CVCL_0168
CHLH-1 (The human squamous lung cancer cell line)
NCI-H226 Pleural epithelioid mesothelioma Homo sapiens CVCL_1544
CHLH-1 (The human squamous lung cancer cell line)
NCI-H520 Lung squamous cell carcinoma Homo sapiens CVCL_1566
References
Ref 1 Kinase GSK3Beta functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis. J Cell Mol Med. 2021 Mar;25(5):2655-2665. doi: 10.1111/jcmm.16291. Epub 2021 Feb 2.
Ref 2 m(6)A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem Biophys Res Commun. 2018 Aug 25;502(4):456-464. doi: 10.1016/j.bbrc.2018.05.175. Epub 2018 Jun 2.